AtriCure’s report of strong sales growth for the 4th quarter and 2013 sends share prices up on Wall Street.
Fresh off of the $34 million acquisition of Estech, AtriCure (NSDQ:ATRC) reported strong sales growth for the 4th quarter and 2013 and predicted even better gains for this year, sending share prices up today on Wall Street.
San Ramon, Calif.-based AtriCure reported preliminary sales of $21.9 million for the 3 months ended Dec. 31, up 19.0% compared with Q4 2012, and full-year preliminary sales of $81.9 million, up 16.7% over 2012.
“We are pleased to report preliminary 4th-quarter and full-year 2013 results which reflect accelerating growth throughout the year and provide a strong platform from which we can continue to build. As we look forward to 2014, we have reason to be excited about our prospects – we are firmly establishing AtriCure as the leader in training and education on atrial fibrillation. Further, we recently strengthened our position through the acquisition of Estech,” president & CEO Mike Carrel said in prepared remarks.
